Archive

02 June 2019, Volume 35 Issue 6 Previous Issue    Next Issue

---

For Selected:

Download Citations EndNote Ris BibTeX

Toggle Thumbnails

Select

Abdominal radical trachelectomy preserving fertility for ⅠB1 cervical cancer patients whose tumor ≥2cm：the evidence and controversy of "Fudan Criteria". LI Jin，WU Xiao-hua 2019, 35(6): 614-618.  DOI: 10.19538/j.fk2019060103 Abstract ( )   Abdominal radical trachelectomy was usually utilized in ⅠB1 cervical cancer patients whose tumor ≥2cm since the procedure removed more parametrial tissue than the vaginal approach.We raised selection criteria for ART in such patients in 2011. In this article，we will further discuss issues regarding fertility-sparing surgery in ⅠB1 cervical cancer with tumor ≥2cm.

Select

Fertility-preserving treatment for early stage endometrial cancer. 2019, 35(6): 618-623.  DOI: 10.19538/j.fk2019060104 Abstract ( )   The fertility preservation treatment has become one of the main issues with the increasing incidence of endometrial cancer.Strict selection of the young endometrial cancer patients who are eligible for fertility preservation treatment and individualized treatment plan are fundamental for improving treatment effect while decreasing the risk of treatment-related complications and treatment failure.This article will discuss the evaluation and treatment choice for fertility preservation in young endometrial cancer patients.

Select

Fertility-sparing treatment for early stage epithelial ovarian cancer. ZHANG Shi-qian，YUAN Hang 2019, 35(6): 623-626.  DOI: 10.19538/j.fk2019060105 Abstract ( )   With the onset age of tumor becoming younger，the preservation of reproductive function of cancer patients has become a hot issue in cancer treatment.Ovarian cancer is one of the most common gynecological malignancies.The fertility-sparing treatment for patients with epithelial ovarian cancer at the childbearing age is receiving increasing attention.This article will address the issues related to the fertility-sparing treatment for patients with early epithelial ovarian cancer.

Select

Fertility preservation in nonepithelial ovarian malignancy. HAN Li-ping，LIU Li-ya 2019, 35(6): 626-631.  DOI: 10.19538/j.fk2019060106 Abstract ( )   Non-epithelial ovarian malignant tumors account for about 10% of ovarian tumors，and mostly develops in young women.Although surgery and radiotherapy and chemotherapy can make patients get the chances of survival，but often lead to different degrees of damage to reproductive function，causing physical and psychological suffering.While improving the survival rate of patients with malignant ovarian tumors，it is an important research issue to protect the reproductive function of patients as much as possible in the treatment of malignant ovarian tumors.The fertility-sparing treatment has a good effect on non-epithelial  ovarian malignant tumors，especially malignant ovarian germ tumors.In this article，we discuss the surgical treatment of fertility protection，the implementation of postoperative adjuvant treatment and the application of assisted reproductive technology in non-epithelial ovarian malignant tumors.

Select

Prevention of chemotherapy-induced ovarian damage in patients with gynecological malignant tumors. YANG Xiao-ming，WANG Yu-dong 2019, 35(6): 631-635.  DOI: 10.19538/j.fk2019060107 Abstract ( )   Improvement in diagnosis has made it possible to have the early detection of gynecologic malignancies.Among premenopausal women，the loss of future fertility or ovarian function is considered among the most dreadful long-term side effects of treatments.Therefore，the preservation of fertility and ovarian function during chemotherapy treatment is of great important.This article will summarize the effect of chemotherapy on ovarian function and protective measures for chemotherapy-induced ovarian damage.

Select

Effect of radiotherapy on the reproductive and endocrine function of women with gynecological malignant tumors. KONG Wei-min，SHANG Ruo-tian 2019, 35(6): 635-638.  DOI: 10.19538/j.fk2019060108 Abstract ( )   Radiotherapy is an important method in the treatment of gynecological malignant tumors，but it also causes great damage to female reproductive and endocrine function.This article reviews the effects of radiotherapy on reproductive and endocrine function in women and protective methods.

Select

Oncological outcomes of the fertility-sparing surgery for the gynecologic malignancies. LI Juan，LI Chang-zhong 2019, 35(6): 638-643.  DOI: 10.19538/j.fk2019060109 Abstract ( )   Cervical cancer，ovarian cancer and endometrial carcinoma are most common maligancies in gynecology.More and more women suffer from gynecologic malignancies at a younger age.For these young women with hoping to preserve fertility，the fertility-sparing surgery without increasing the rise of tumor has been paid much attention.How are the oncological outcomes of these patients after the fertility-sparing surgeries ? We try to discuss this in the article.

Select

Gynecological malignant tumor and assisted reproductive technology. DENG Xiao-hui，CUI Yan-ting 2019, 35(6): 644-646.  DOI: 10.19538/j.fk2019060110 Abstract ( )   The age of onset of gynecological malignant tumors tends to be younger，more and more patients have fertility requirements when they are diagnosed with cancer.Different cancer treatments have a certain impact on the fertility of patients, application of assisted reproductive technology（ART）can help part of the patients fulfill their fertility wish. In this paper, the methods and safety of ART for three gynecological malignant tumors are discussed.

Select

Reproductive outcomes of fertility-sparing treatment for gynecologic malignancies. XUE Feng-xia，TENG Fei 2019, 35(6): 646-651.  DOI: 10.19538/j.fk2019060111 Abstract ( )   Cervical cancer，endometrial cancer and ovarian cancer are common gynecologic malignancies.Recently，with the younger onset age and delay of childbearing，the fertility-sparing treatment has been increasingly used.In the fertility-sparing treatment for gynecologic malignancies，we should protect the fertility of patients without increasing tumor recurrence，which requires the multidisciplinary cooperation to develop individualized treatment strategy，provide optimal reproductive guidance and finally improve the reproductive outcomes.

Select

Hormone therapy and its risk after gynecological malignancy operation. CHEN Rong，WANG Hui-ling 2019, 35(6): 651-654.  DOI: 10.19538/j.fk2019060112 Abstract ( )   With the improvement of therapy，the survival time of patients with gynecological malignant tumor is prolonged，so improving their quality of life has become a new challenge for doctors.These patients may be in perimenopause themselves，or be in artificial menopause due to tumor treatment，and their climacteric symptoms are more obvious than those in natural menopause.Whether hormone therapy could be used to relieve the climacteric symptoms in these patients is still controversial at present.Clinicians should give individualized hormone therapy cautiously on the basis of patients' informed consent.